Dec 21, 2023
Beginning January 15, 2024, our collaborators at the Hough Ear Institute (HEI) will be offering Tinnitus Together, the first peer-to-peer tinnitus support group in the State of Oklahoma. This no-cost support group will be led by a licensed professional counselor,...
Apr 13, 2023
https://www.fiercebiotech.com/biotech/boehringer-okays-100m-biobuck-deal-hearing-loss-rd-project
Mar 27, 2023
https://www.tinnitusjournal.com/articles/response-to-okn007-and-nac-in-a-patient-with-unilateral-hearing-loss-and-chronic-tinnitus-from-vestibular-schwannoma.pdf
Dec 22, 2022
https://pubmed.ncbi.nlm.nih.gov/36240574/
Dec 16, 2021
Articles about us: Oblato Acquires Rights to Hearing Loss Drug (https://hearingreview.com/inside-hearing/research/hei)Bringing Back Silence (https://houghear.org/bringing-back-silence/) Noteworthy News: Our President, Dr. Elaine Hamm, was an invited speaker to the...
Jan 7, 2021
https://pubmed.ncbi.nlm.nih.gov/33411811/
Apr 27, 2018
FOR IMMEDIATE RELEASE Potential Hearing Loss Drug Featured in The Scientist Otologic Pharmaceutics, in collaboration with the Hough Ear Institute, has developed a new drug that could restore hearing Through siRNA therapy, OPI/HEI scientists are able to regrow lost or...
Oct 1, 2017
Only Funded Application Among 73 Applicants Otologic Pharmaceutics, Inc. (OPI), in alliance with The Hough Ear Institute (HEI), announces the award of a Congressionally Directed Medical Research Programs (CDMRP) grant from the Department of Defense. The grant of $1.9...
Dec 1, 2015
Otologic Pharmaceutics, Inc. (OPI), a development-stage biopharmaceutical company committed to developing and commercializing novel pharmacological solutions and approaches to treat hearing disorders, announced the successful completion of single and multi-dose Phase...
Apr 3, 2014
Financing to Support Entry of OPI’s Lead Product Candidate – NHPN-1010 – into Clinical Testing First Half of 2014 OKLAHOMA CITY, April 3, 2014 /PRNewswire/ — Accele Venture Partners, the investing arm of life sciences accelerator Accele Biopharma, Inc.,...
